http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-063332-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10 |
| filingDate | 2007-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-063332-A1 |
| titleOfInvention | DERIVATIVES OF IMIDAZOLONA AND IMIDAZOLIDINONA AS INHIBITORS OF 11B-HSD1, A PREPARATION PROCESS AND A PHARMACEUTICAL COMPOSITION BASED ON THE COMPOSITE |
| abstract | These compounds can be used as medicines for the treatment of diabetes, dyslipitemias, obesity and hypertension. 1. The compounds of formula (1) in which R1 is a) bornyl, norbornyl, adamantyl or adamantyl substituted with one or two substituents independently selected from the following: hydroxy, alkoxy, halogen, alkyl, hydroxyalkyl, amino, aminocarbonyl, alkoxycarbonyl, hydroxycarbonyl, alkylcarbonylamino, alkyl-S (O) 2-amino, haloalkyl-S (O) 2- amino, alkoxycarbonylamino-S (O) 2-amino, amino-S (O) 2-amino, hydroxyalkylcarbonylamino, aminocarbonylamino and haloalkoxy; b) trifluoromethylphenyl, methoxyphenyl, haloalkoxyphenyl or difluorophenyl, in which trifluoromethylphenyl, haloalkoxyphenyl and difluorophenyl are optionally substituted with one or two substituents independently selected from the following: alkyl, halogen, haloalkyl, alkoxy, hydroxy and haloalkoxy; c) trifluoromethylphenylalkyl or trifluoromethylphenylalkyl substituted with one or two substituents independently selected from the following: alkyl, halogen, haloalkyl, alkoxy, hydroxy and haloalkoxy; d) phenylcycloalkyl or phenylcycloalkyl substituted with a number of substituents of one to three independently selected from the following alkyl, halogen, haloalkyl, alkoxy, hydroxy and haloalkoxy; e) cyanophenyl or halogen substituted cyanophenyl; or f) dihalophenyl, aminocarbonylphenyl or hydroxyphenyl, wherein the aminocarbonylphenyl and hydroxyphenyl are optionally substituted with one or two substituents independently selected from the following: alkyl, halogen, haloalkyl, alkoxy and haloalkoxy; R2 is hydrogen, alkyl, alkenyl, haloalkyl, pyridinylalkyl, cycloalkyl, cycloalkylalkyl or phenylalkyl, or R2 is pyridinylalkyl or phenylalkyl in which both are substituted with a number of substituents from one to three independently selected from the following: alkyl, hydroxy, alkoxy , halogen, haloalkyl and haloalkoxy; one between R3 and R4 is hydrogen, alkyl, cycloalkyl, haloalkyl or does not exist and the other is: a) hydrogen, alkyl, pyridinyl, cycloalkyl, cycloalkylalkyl or haloalkyl; b) phenyl or phenyl substituted with a number of substituents of one to three independently selected from the following fluoro, chloro, bromo, haloalkyl, alkoxy, hydroxy, haloalkyl and haloalkoxy; c) phenylalkyl or pyridinylalkyl in which phenylalkyl and pyridinylalkyl are optionally substituted with a number of substituents from one to three independently selected from the following alkyl, halogen, haloalkyl and hydroxy; d) oxetane or oxetane substituted with an alkyl group; e) naphthyl or tetrahydronaphthyl; f) phenylalkoxyalkyl or phenylalkoxyalkyl substituted with a number of substituents from one to three independently selected from the following: alkyl and halogen; g) hydroxyalkyl; or h) pyridinyloxyalkyl or pyridinyloxyalkyl substituted with a cyano group; or R3 and R4 together with the carbon atom to which they are attached form a cycloalkane, piperidine, tetrahydropyran, tetrahydrothiopyran, pyrrolidine, tetrahydrofuran, indane or oxetane, in which cycloalkyl, piperidine, tetrahydropyran, tetrahydrothiopyran, pyrrolidine, tetrahydrofuran, Oxetane is optionally substituted with a number of substituents from one to three independently selected from the following: alkyl, aryl and arylalkyl; one of the radicals R5 or R6 is hydrogen, isopropyl, isobutyl, cycloalkyl or haloalkyl and the other is hydrogen or does not exist; and pharmaceutically acceptable salts and esters thereof provided that 1,3-dihydro-4-phenyl-1- (3- (trifiuoromethyl) phenyl) -2H-imidazol-2-one is excluded and, in the case of If one of the radicals R3 is methyl, ethyl, n-propyl or n-butyl and the other is hydrogen or does not exist, then R2 is neither hydrogen nor methyl. |
| priorityDate | 2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.